finding that the knockout negatively impacted HSCs and immune cells with B cell lineage (types of white blood cells) but had ...

Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid ...

Several cell-surface antigen molecules were developed ... Transplant tests using pure HSCs were also performed to compare the myeloid and lymphoid lineage potential in recipient mice.

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious ...